Federal Register of Legislation - Australian Government

Primary content

PB 32 of 2012 Arrangements as made
This instrument amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (No. PB 79 of 2011) making changes to the special arrangement relating to the efficient funding of chemotherapy.
Administered by: Health
Registered 30 Apr 2012
Tabling HistoryDate
Tabled HR08-May-2012
Tabled Senate10-May-2012
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

PB 32 of 2012

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 3)

 

National Health Act 1953

___________________________________________________________________________

 

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.

Dated  26 April 2012

 

 

 

 

 

 

 

 

 

 

 

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

___________________________________________________________________

 

 

 

 

 

1              Name of Instrument

 

(1)                This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 3).

 

(2)                This Instrument may also be cited as PB 32 of 2012.

 

2             Commencement

                This Instrument commences on 1 May 2012.

3              Amendments to PB 79 of 2011

                      Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).

 

 


Schedule 1                   Amendments

 

[1]    Schedule 1 Part 1, entry for Carboplatin in the form Solution for I.V. injection 50 mg in 5 mL with manner of administration Injection

omit:

 

 

 

Pfizer Australia Pty Ltd

PF

MP

 

D

 

[2]    Schedule 1 Part 1, entry for Cisplatin

omit:

 

I.V. injection 10 mg in 10 mL

Injection

Pfizer Australia Pty Ltd

PF

MP

 

D

 

[3]    Schedule 1 Part 1, entry for Doxorubicin in the form Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 mL single dose vial with manner of administration Injection/intravesical

omit:

 

 

 

Adriamycin Solution

PF

MP

 

D

 

[4]    Schedule 1 Part 1, entry for Doxorubicin

omit:

 

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 20 mg in 10 mL single dose vial

Injection/ intravesical

Adriamycin Solution

PF

MP

 

D

 

[5]    Schedule 1 Part 1, after entry for Doxorubicin - Pegylated Liposomal in the form Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL with manner of administration Injection and brand Caelyx

insert in the columns in the order indicated:

 

 

 

Lipodox

ZF

MP

C1568 C1795 C1796 C3905 C3910 C3911

D

 

 

 

 

[6]    Schedule 1 Part 1, after entry for Doxorubicin - Pegylated Liposomal in the form Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL with manner of administration Injection and brand Caelyx

insert in the columns in the order indicated:

 

 

 

Lipodox 50

ZF

MP

C1568 C1795 C1796 C3905 C3910 C3911

D

 

[7]    Schedule 1 Part 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 10 mg in 5 mL with manner of administration Injection/intravesical

omit:

 

 

 

Pharmorubicin Solution

PF

MP

 

D

 

[8]    Schedule 1 Part 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 20 mg in 10 mL with manner of administration Injection/intravesical

omit:

 

 

 

Pharmorubicin Solution

PF

MP

 

D

 

[9]    Schedule 1 Part 1, entry for Irinotecan in the form I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL with manner of administration Injection

omit:

 

I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL

Injection

Camptosar

PF

MP

C3184

D

 

 

 

Hospira Pty Limited

HH

MP

C3184

D

substitute:

 

I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL

Injection

Hospira Pty Limited

HH

MP

C3184

D

 

[10]  Schedule 1 Part 1, entry for Mitozantrone

omit:

 

Injection 10 mg (as hydrochloride) in 5 mL

Injection

Pfizer Australia Pty Ltd

PF

MP

 

D

 

 

 

[11]  Schedule 1 Part 1, entry for Mitozantrone in the form Injection 25 mg (as hydrochloride) in 12.5 mL with manner of administration Injection

omit:

 

 

 

Pfizer Australia Pty Ltd

PF

MP

 

D

 

[12]  Schedule 1 Part 1, entry for Oxaliplatin in the form Powder for I.V. infusion 100 mg with manner of administration Injection

omit:

 

 

 

Winthrop Oxaliplatin

WA

MP

C3900 C3901 C3930 C3939

D

 

[13]  Schedule 1 Part 1, entry for Vincristine in the form I.V. injection containing vincristine sulfate 1 mg in 1 mL with manner of administration Injection

omit:

 

 

 

Pfizer Australia Pty Ltd

PF

MP

 

D

 

[14]  Schedule 2, entry for Ondansetron in the form I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL with manner of administration Injection

omit:

 

 

 

Pfizer Australia Pty Ltd

PF

EMP

C3050

 

1

0

 

 

[15]  Schedule 2, entry for Ondansetron in the form I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL with manner of administration Injection

omit:

 

 

 

Pfizer Australia Pty Ltd

PF

EMP

C3050

 

1

0

 

 

[16]  Schedule 3, omit entry for WA

 

[17]  Schedule 5, before entry for Bleomycin in the form Powder for injection containing bleomycin sulfate 15,000 I.U. with manner of administration Injection and brand Hospira Pty Ltd

insert:

Bleomycin

Powder for injection containing bleomycin sulfate 15,000 I.U.

Injection

Bleo 15K

1

$34.35

$65.24

 

[18]  Schedule 5, entry for Bleomycin in the form Powder for injection containing bleomycin sulfate 15,000 I.U. with manner of administration Injection and brand Hospira Pty Ltd

omit from the column headed ‘Listed Drug’:

Bleomycin

[19]  Schedule 5, entry for Bleomycin in the form Powder for injection containing bleomycin sulfate 15,000 I.U. with manner of administration Injection and brand Hospira Pty Ltd

omit from the column headed ‘Form’:

Powder for injection containing bleomycin sulfate 15,000 I.U.

[20]  Schedule 5, entry for Bleomycin in the form Powder for injection containing bleomycin sulfate 15,000 I.U. with manner of administration Injection and brand Hospira Pty Ltd

omit from the column headed ‘Manner of Administration’:

Injection

 

Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 

See http://www.frli.gov.au.